And secondly, this 2D exciton is stable at room temperature and
robust against defects, as it is present in any type of TiO2 — single crystals, thin films, and even nanoparticles used in devices.
«We're highly encouraged by these preclinical findings demonstrating the ability of our mRNA vaccine to provide
robust prevention of maternal transmission of Zika and protection
against congenital
defects,» said Giuseppe Ciaramella, Ph.D., Chief Scientific Officer of Moderna's infectious disease - focused venture, Valera, and an author on the paper.